Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
CervoMed Inc. is a clinical-stage biotechnology company developing treatments for age-related neurological disorders. Its lead candidate, neflamapimod, is an oral small molecule targeting neuroinflammation and synaptic dysfunction in diseases like dementia with Lewy bodies (DLB), FTD, and stroke recovery. The company focuses on early intervention, leveraging its understanding of neurodegenerative mechanisms to slow or reverse disease progression.
This description was generated via AI from an annual report. Updated about 1 year ago.